Mammary Cell News Volume 8.19 | May 19 2016

    0
    45
    Mammary Cell News 8.19 May 19, 2016

    Mammary Cell News

         In this issue: Publications | Reviews | Science News | Industry News | Policy News | Events | Jobs
    Cell Therapy News on Facebook  MCN on Twitter

     
    TOP STORY
    Breast Cancer Tumor-Initiating Cells Use mTOR Signaling to Recruit Suppressor Cells to Promote Tumor Growth
    Not every breast cancer tumor follows the same path to grow. Some tumors have the assistance of myeloid-derived suppressor cells (MDSCs), a diverse type of immune cell involved in the suppression of the body’s response against tumors. How breast cancer cells recruit MDSCs is not completely understood, but researchers report a new mechanism that helps cancer cells engage MDSCs. [Press release from the Baylor College of Medicine discussing online publication in Nature Cell Biology.] Press Release | Abstract
    Culture and Characterize Human Mammary Epithelial Progenitors with Serum-Free EpiCult-B (Human) Free Protocols

     
    PUBLICATIONS (Ranked by impact factor of the journal)
    LABORATORY RESEARCH

    RAC1 GTPase Promotes the Survival of Breast Cancer Cells in Response to Hyper-Fractionated Radiation Treatment
    The authors investigated the effect of Rac1 on the survival of breast cancer cells treated with hyper-fractionated radiation, which is used clinically for cancer treatment. [Oncogene] Abstract

    The C/EBPδ Protein Is Stabilized by Estrogen Receptor α Activity, Inhibits SNAI2 Expression and Associates with Good Prognosis in Breast Cancer
    Scientists report a different role for Ccaat/enhancer-binding protein δ (C/EBPδ, CEBPD) in breast cancer. They found that the C/EBPδ protein is expressed in normal breast epithelial cells and in low-grade cancers. [Oncogene] Abstract

    CAP1 (Cyclase-Associated Protein 1) Exerts Distinct Functions in the Proliferation and Metastatic Potential of Breast Cancer Cells Mediated by ERK
    Scientists found that CAP1 exerts cell type-dependent functions in the invasiveness of breast cancer cells. Depletion of CAP1 in the metastatic MDA-MB-231 and BT-549 cancer cells stimulated the metastatic potential while it actually inhibited it in the non-metastatic MCF-7 cancer cells or in normal cells. [Sci Rep] Full Article

    Slug-Upregulated miR-221 Promotes Breast Cancer Progression through Suppressing E-Cadherin Expression
    Researchers reveal a novel mechanism that E-cadherin is post-transcriptionally regulated by Slug-promoted miR-221, which serves as an additional blocker for E-cadherin expression in metastatic tumor cells. [Sci Rep] Full Article

    CD24 Cell Surface Expression in Mvt1 Mammary Cancer Cells Serves as a Biomarker for Sensitivity to Anti-IGF1R Therapy
    The authors demonstrated that downregulation of the insulin-like growth factor receptor (IGF1R) specifically in cancer cells expressing CD24 on the cell surface membrane affect both their morphology (from mesenchymal-like into epithelial-like morphology) and phenotype in vitro. [Breast Cancer Res] Full Article

    Heregulin/ErbB3 Signaling Enhances CXCR4-Driven Rac1 Activation and Breast Cancer Cell Motility via HIF-1α
    Investigators found that breast cancer cells exposed to sustained growth factor heregulin treatment show markedly enhanced Rac1 activation and migratory activity in response to the CXCR4 ligand SDF-1/CXCL12, effects mediated by P-Rex1, a Rac-GEF aberrantly expressed in breast cancer. [Mol Cell Biol] Abstract

    Janus Kinase 1 Is Essential for Inflammatory Cytokine Signaling and Mammary Gland Remodeling
    Using a novel mammary gland-specific JAK1 knockout model, researchers demonstrated that this tyrosine kinase is essential for the activation of STAT1, STAT3, and STAT6 in the mammary epithelium. [Mol Cell Biol] Abstract

    CLINICAL RESEARCH

    Neoadjuvant Sequential Docetaxel followed by High-Dose Epirubicin in Combination with Cyclophosphamide Administered Concurrently with Trastuzumab: The DECT Trial
    Investigators report the results of the DECT trial, a Phase II study of locally advanced or operable HER2-positive breast cancer treated with taxanes and concurrent anthracyclines and trastuzumab. [J Cell Physiol] Abstract

    Deficiency of Mitochondrial Modulator MCJ Promotes Chemoresistance in Breast Cancer
    Methylation-controlled J protein (MCJ, also known as DNAJC15) is a negative regulator of mitochondrial respiration and has been associated with chemotherapeutic drug sensitivity in cancer cell lines. Investigators showed, in a retrospective study of a large cohort of breast cancer patients, that low MCJ expression in breast tumors predicts high risk of relapse in patients treated with chemotherapy; however, MCJ expression did not correlate with response to endocrine therapy. [JCI Insight] Full Article | Press Release

    Request a Copy: Breast Cancer Wallchart

     
    REVIEWS
    Triple-Negative Breast Cancer: Challenges and Opportunities of a Heterogeneous Disease
    The authors discuss the most relevant molecular findings in triple-negative breast cancer from the past decade and the most promising therapeutic opportunities derived from these data. [Nat Rev Clin Oncol] Abstract

    Visit our reviews page to see a complete list of reviews in the mammary cell research field.

     
    SCIENCE NEWS
    Merrimack Presents Expanded Analysis from Seribantumab (MM-121) Phase II Breast Cancer Study at the AACR Precision Medicine Series
    Merrimack Pharmaceuticals, Inc. presented an expanded analysis of its Phase II study of seribantumab (MM-121) in combination with exemestane in HER2-negative, hormone receptor positive metastatic breast cancer. [Press release from Merrimack Pharmaceuticals, Inc. discussing research presented at the American Association for Cancer Research (AACR) Precision Medicine Series: Targeting the Vulnerabilities of Cancer, Miami] Press Release

    From our sponsor:
    Discover how to reduce variability in primary neuron cultures with NeuroCult™ SM.
    Watch the webinar.

     
    INDUSTRY NEWS
    A Persistent Pioneer in Breast Cancer Research
    Dr. Carol Fabian was honored for her work changing the odds for women with breast cancer and those at increased risk for the disease. [University of Kansas] Press Release

    Cancer Research UK Invests £16 Million into Hard to Treat Cancers
    Cancer Research UK UCL Centre will receive £4 million to roll out a national post-mortem tissue bank from patients with hard to treat and metastatic cancer. This study will be vital for understanding the evolution and final stages of the disease and researching the genetics of brain tumors which are hard for doctors to take samples from when patients are alive. [Cancer Research UK] Press Release

    SmartPractice donates $50,000 to TGen cancer research
    SmartPractice donated $50,000 to the Translational Genomics Research Institute (TGen) to support research for the early detection and more precise treatment of breast cancer. [Translational Genomics Research Institute] Press Release

     
    POLICY NEWS
    National Institutes of Health (United States)

    Food and Drug Administration (United States)

    Center for Biologics Evaluation and Research (United States)

    European Medicines Agency (European Union)

    Medicines and Healthcare Products Regulatory Agency (United Kingdom)

    Therapeutic Goods Administration (Australia)

     
    EVENTS
    NEW European Society for Medical Oncology (ESMO) 2016
    October 7-11, 2016
    Copenhagen, Denmark

    Visit our events page to see a complete list of events in the mammary cell community.

     
    JOB OPPORTUNITIES
    NEW Senior Research Technician – Breast Cancer (Kings College London)

    NEW Scientific Communications and Publishing Coordinator (STEMCELL Technologies Inc.)

    Research Technologist – Mammary and Prostate Stem Cell Biology (STEMCELL Technologies Inc.)

    PhD Fellow – Small X-Ray Angle for Breast Cancer Diagnosis (CEA Tech)

    Postdoctoral Fellow(s) – Various Projects (National University of Singapore)

    Research Associate – Various Medical Disciplines (Jinan University)

    Postdoctoral Fellow – RNA Splicing in Breast Cancer (Memorial Sloan Kettering Cancer Center)

    Scientist – Cancer Research (Institute of Clinical Physiology)

    Postdoctoral Fellow – Metastatic Reactivation of Cancer (MD Anderson Cancer Center)

    Faculty Position – Cancer Immunology (University of New Mexico)

    Faculty Position – Cancer Research (Eppley Institute for Research in Cancer)

    Postdoctoral Fellow – Breast Cancer (Northwestern University)

    Faculty Position – Tumor Immunology (John Wayne Cancer Institute at Providence Saint John’s Health Center)

    Postdoctoral Fellowship РPlatelets in Metastatic Breast and Colon Cancer (Universit̩ de Strasbourg)

    Manager – Medical and Breast Imaging (Fred Hutchinson Cancer Research Center)

    Director Clinical Research – Medical Oncology (Fred Hutchinson Cancer Research Center)


    Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

     

    Have we missed an important article or publication in Mammary Cell News? Click here to submit!

    Comments or suggestions? Submit your feedback here

    Learn more about Mammary Cell News: Archives | Events | Contact Us